Related Experiment Video

Updated: Dec 30, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2

Atieh Moradimotlagh1, Ehsan Arefian1, Rezvan Rezazadeh Valojerdi1

  • 1Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.

Molecular Therapy. Nucleic Acids
|January 19, 2020
PubMed

Insights

MicroRNA-129 (miR-129) effectively suppresses glioblastoma growth by downregulating key genes like CDK4, CDK6, and MDM2. This study identifies miR-129 as a potential therapeutic target for glioblastoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Glioblastoma is a highly aggressive primary brain tumor with poor prognosis.
  • Dysregulated signaling pathways contribute to glioblastoma's rapid proliferation and survival.
  • MicroRNAs (miRNAs) are crucial regulators of gene expression involved in various cellular functions.

Purpose of the Study:

  • To investigate the role of miR-129 in glioblastoma.
  • To identify specific glioblastoma-associated genes targeted by miR-129.
  • To evaluate the effect of miR-129 on glioblastoma cell proliferation and cell cycle progression.

Main Methods:

  • Real-time PCR to quantify gene expression levels.
  • Luciferase assays to confirm direct targeting of genes by miR-129.
  • Cell cycle analysis and wound healing assays to assess cellular effects.

Main Results:

  • Overexpression of miR-129 significantly reduced the expression of CDK4, CDK6, and MDM2 in glioblastoma cell lines.
  • miR-129 overexpression led to a decrease in the G2-phase cell population and induced G2 arrest.
  • miR-129 was confirmed to directly target and downregulate CDK4, CDK6, and MDM2.
  • Inhibition of glioblastoma cell growth was observed following miR-129 overexpression.

Conclusions:

  • miR-129 acts as a tumor suppressor in glioblastoma by targeting critical genes in the retinoblastoma and p53 signaling pathways.
  • miR-129 demonstrates potential as a therapeutic agent for glioblastoma.
  • Novel therapeutic targets for glioblastoma involving miR-129 have been identified.
Keywords:
CDK4CDK6MDM2cell cycleglioblastomamiR-129

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.9K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K